Crossmark

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets

Crossref DOI link: https://doi.org/10.1186/s13058-020-01324-4

Published Online: 2020-08-11

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kurozumi, Sasagu

Alsaleem, Mansour

Monteiro, Cíntia J.

Bhardwaj, Kartikeya

Joosten, Stacey E. P.

Fujii, Takaaki

Shirabe, Ken

Green, Andrew R.

Ellis, Ian O.

Rakha, Emad A.

Mongan, Nigel P.

Heery, David M.

Zwart, Wilbert

Oesterreich, Steffi

Johnston, Simon J.
Funding

Funding for this research was provided by:

Wellcome Trust (AAM127669)

Susan G. Komen (SAC160073)
License Information

Text and Data Mining valid from 2020-08-11

Version of Record valid from 2020-08-11
More Information

Article History

Received: 21 January 2020

Accepted: 26 July 2020

First Online: 11 August 2020

Ethics approval and consent to participate

: Ethics approvals and consent for each cohort (METABRIC, TCGA, and MSK-IMPACT) was obtained in the original studies.

: Not applicable

: Since the first submission of the article, the corresponding author (SJJ) has moved employment to AstraZeneca, with no competing interests to declare. All other authors declare that they have no competing interests.

Document is current

Any future updates will be listed below